Identification of Usp8 as a toxicity modifying deubiquitinase for α-synuclein
Objective: To study whether ubiquitination in Lewy bodies is directly relevant to α-synuclein turnover and Parkinson's pathogenesis. Background: In Parkinson's disease, misfolded α-synuclein accumulates, often…Human-derived α-synuclein antibody BIIB054 binds pathologic forms of α-synuclein and attenuates transmission of α-synuclein in vitro and in vivo
Objective: To identify and characterize a human antibody against α-synuclein (α-syn) for the clinical development of an immunotherapy for Parkinson's disease (PD). Background: α-syn plays…Cell-surface expression of dopamine transporter facilitates the uptake of α-synuclein
Objective: We determined whether increased expression of DAT have an impact on the uptake of α-synuclein (αS). Background: The endocytosis of dopamine transporter (DAT) controls…Novel small molecules targeting alpha-synuclein aggregation for the treatment of Parkinson’s disease
Objective: To develop novel, small molecular weight compounds, that can interfere with the aggregation process of alpha-synuclein (aSyn), as disease modifying agents. Background: The aggregation…Modulation of microglia function in the prion-like spreading of α-synuclein in the murine brain
Objective: We aimed to analyze the influence of two microglia-related pathways on the accumulation of α-synuclein aggregates and neurodegeneration after intracerebral injection of sonicated murine…The systemic synuclein sampling study (S4)
Objective: The Systemic Synuclein Sampling Study (S4) is designed to characterize the distribution of alpha-synuclein (α-syn) pathology in multiple tissues and biofluids in Parkinson's disease…Neurodegeneration and microgliosis are independent of α-synuclein aggregation in a mouse model of "prion-like" α-synuclein speading
Objective: Our aim was to test if α-synclein aggregation drives neuronal demise and microglial activation in a murine model of induced-α-synucleinopathy. Background: Pathological α-synuclein aggregates…Lewy body extracts from Parkinson’s disease brains as models for high-throughput screens of neurotoxicity and α-synuclein spreading from cell-to-cell
Objective: To validate the effect of Lewy body extracts from Parkinson's disease (PD) brains in high-throughput screens of neurotoxicity and the α-synuclein (α-syn) spreading from…Alpha synuclein and crystallin expression in human lens in Parkinson’s disease
Objective: To determine the Protein Profile of cataract lenses in Parkinson's disease (PD). Background: Protein accumulation, mainly αB-crystallin, in the lens causes cataract. PD is…Characteristics of the interaction between different toxic aggregated species of alpha-synuclein and cell membrane
Objective: To determine (1) the interaction rate of each toxic aggregated species of alpha-synuclein (α-Syn) with cell membrane compare to the monomeric form, (2) the…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.